Drugs / Bimosiamose
Bimosiamose
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00962481 Comparator | — | chronic obstructive pulmonary disease | Revotar Biopharmaceuticals AG | Completed | No outcome recorded |
| Phase 2 | NCT01108913 Comparator | — | chronic obstructive pulmonary disease | Revotar Biopharmaceuticals AG | Completed | No outcome recorded |
| Phase 2 | NCT00823693 Comparator | — | psoriasis | Revotar Biopharmaceuticals AG | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bimosiamose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01108913 ↗ |
| Known as | Bimosiamosa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1215923 ↗ |
| Known as | BIMOSIAMOSE DISODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1215923 ↗ |
| Known as | Bimosiamose disodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1215923 ↗ |
| Known as | TBC-1269 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1215923 ↗ |
| Known as | TBC-1269Z | ChEMBL registry synonym — accepted as the source's own label CHEMBL1215923 ↗ |
| Action | Inhibit | “pan-selectin antagonist Bimosiamose” PMID 23257347 ↗ Dec 2012 |
| Modality | Small molecule | — CHEMBL1215923 ↗ |
| Route | Inhaled | “repeated inhalative doses of Bimosiamose” NCT00962481 ↗ |